Human Papillomavirus Same Genotype Persistence and Risk of Cervical Intraepithelial Neoplasia 2+ Recurrence
| Autor: | Dorella Franchi, Fabio Bottari, Davide Radice, Eleonora Petra Preti, Rita Passerini, Maria Elena Guerrieri, Ida Pino, Ailyn Mariela Vidal Urbinati, Anna Daniela Iacobone, Maria Teresa Sandri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty test-of-cure Hpv persistence Article Persistence (computer science) 03 medical and health sciences 0302 clinical medicine Internal medicine Genotype medicine HPV 16/18 Human papillomavirus Prospective cohort study RC254-282 treatment failure 030219 obstetrics & reproductive medicine business.industry Incidence (epidemiology) Neoplasms. Tumors. Oncology. Including cancer and carcinogens HPV genotyping Multiple infections HPV persistence High-Risk genotypes Oncology CIN2+ recurrence 030220 oncology & carcinogenesis business multiple HPV infections After treatment |
| Zdroj: | Cancers Volume 13 Issue 15 Cancers, Vol 13, Iss 3664, p 3664 (2021) |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13153664 |
| Popis: | To evaluate the significance of HPV persistence as a predictor for the development of CIN2+ recurrence and the impact of multiple genotypes and of HPV 16/18 on recurrence risk. A prospective cohort observational study was carried out at the European Institute of Oncology, Milan, Italy, from December 2006 to December 2014. A total of 408 women surgically treated by excisional procedure for pre-neoplastic and neoplastic cervical lesions were enrolled. HPV test was performed at baseline and at first follow-up visit planned at 6 ± 3 months after treatment. Two-year cumulative incidences for relapse were estimated and compared by the Gray’s test. Overall, 96 (23.5%) patients were persistent for at least one genotype at three to nine months from baseline and 21 (5.1%) patients relapsed. The two-year cumulative relapse incidence was higher in HPV persistent patients compared to not-persistent (CIF = 27.6%, 95% CI: 16.2–40.2% versus CIF = 1.7%, 95% CI: 0.3–5.8%, p < 0.001), in women with persistent multiple infections (CIF = 27.2%, 95% CI: 7.3–52.3%, p < 0.001), and with the persistence of at least one genotype between 16 and 18, irrespective of the presence of other HR genotypes (CIF = 32.7%, 95% CI: 17.9–48.3%, p < 0.001), but not significantly different from women positive for single infections or any other HR genotype, but not for 16 and 18. The risk of CIN2+ recurrence should not be underestimated when same HPV genotype infection persists after treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|